R115777 Induces Reductions in Bone Marrow Blasts
July 01, 2002
NANTES, France-The farnesyl transferase inhibitor R115777 (tipifarnib, also known as Zarnestra) is well-tolerated and effective even in relapsed, refractory acute myelogenous leukemia (AML), according to interim results of a phase II study (ASCO abstract 1056). "In this multicenter trial, we have treated relapsed and refractory patients including those who never had a complete response," lead author Jean-Luc Harousseau, MD, professor and head of the hematology department at University Hospital (hotel Dieu) in Nantes, France, told Oncology News International. "Disappearance of blasts and complete response is very encouraging for the future of Zarnestra in AML."